Impact of COVID-19 infection on patients admitted with nonvariceal upper gastrointestinal bleeding: an analysis from the National Inpatient Sample.
COVID-19
SARS-CoV-2
upper gastrointestinal bleeding
Journal
Proceedings (Baylor University. Medical Center)
ISSN: 0899-8280
Titre abrégé: Proc (Bayl Univ Med Cent)
Pays: United States
ID NLM: 9302033
Informations de publication
Date de publication:
2024
2024
Historique:
medline:
4
1
2024
pubmed:
4
1
2024
entrez:
4
1
2024
Statut:
epublish
Résumé
Nonvariceal upper gastrointestinal bleeding (NVUGIB) is a medical emergency that has significant morbidity and mortality. The available data about the impact of COVID-19 infection on mortality in patients with NVUGIB is limited. We identified all hospitalizations with a principal diagnosis of NVUGIB in 2020. The baseline characteristics and clinical outcomes of patients with COVID-19 infection were compared to those without COVID-19 infection. NVUGIB patients with COVID-19 infection had higher mortality (5% vs 2%, COVID-19 infection is an independent predictor of mortality in adults hospitalized with NVUGIB.
Sections du résumé
Background
UNASSIGNED
Nonvariceal upper gastrointestinal bleeding (NVUGIB) is a medical emergency that has significant morbidity and mortality. The available data about the impact of COVID-19 infection on mortality in patients with NVUGIB is limited.
Methods
UNASSIGNED
We identified all hospitalizations with a principal diagnosis of NVUGIB in 2020. The baseline characteristics and clinical outcomes of patients with COVID-19 infection were compared to those without COVID-19 infection.
Results
UNASSIGNED
NVUGIB patients with COVID-19 infection had higher mortality (5% vs 2%,
Conclusions
UNASSIGNED
COVID-19 infection is an independent predictor of mortality in adults hospitalized with NVUGIB.
Identifiants
pubmed: 38174004
doi: 10.1080/08998280.2023.2260280
pii: 2260280
pmc: PMC10761015
doi:
Types de publication
Journal Article
Langues
eng
Pagination
36-41Informations de copyright
Copyright © 2023 Baylor University Medical Center.
Déclaration de conflit d'intérêts
Khaled Elfert, MD, received a travel grant for the abstract titled “Trends, characteristics, and outcomes of hospitalized patients with primary sclerosing cholangitis in the United States” that was presented at the Digestive Disease Week. Michel Kahaleh, MD, has received grant support from Boston Scientific, Fujinon, Apollo Endosurgery, Cook Endoscopy, Olympus, and MI Tech. He is a consultant for Boston Scientific and ABBvie. None of that funding was related to this paper. The other authors report no funding or potential conflicts of interest.